docetaxel accord 20mg/1ml concentrate for solution for infusion concentrate for solution for infusion
accord healthcare polska sp. z o.o. - docetaxel - concentrate for solution for infusion - 20mg/ml
docetaxel accord 20mg/1ml concentrate for solution for infusion concentrate for solution for infusion
accord healthcare polska sp. z o.o. - docetaxel - concentrate for solution for infusion - 20mg/ml
docetaxel accord 80mg/4ml concentrate for solution for infusion concentrate for solution for infusion
accord healthcare polska sp. z o.o. - docetaxel - concentrate for solution for infusion - 20mg/ml
docetaxel accord 160mg/8ml concentrate for solution for infusion concentrate for solution for infusion
accord healthcare polska sp. z o.o. - docetaxel - concentrate for solution for infusion - 20mg/ml
docetaxel 20mg/ml concentrate for solution for infusion
seacross pharmaceuticals limited - docetaxel anhydrous - concentrate for solution for infusion - 20 milligram(s)/millilitre - taxanes; docetaxel
docetaxel aqvida 20 mg per 1 ml solution for infusion
aqvida gmbh, germany - docetaxel - solution for infusion - 20 mg/ml,
docetaxel aqvida 80 mg per 4 ml solution for infusion
aqvida gmbh, germany - docetaxel - solution for infusion - 20 mg/ml,
docetaxel aqvida 160 mg per 8 ml solution for infusion
aqvida gmbh, germany - docetaxel - solution for infusion - 20 mg/ml,
taxotere
sanofi - aventis israel ltd - docetaxel as trihydrate 20 mg / 1 ml - concentrate for solution for infusion - docetaxel - breast cancer: taxotere (docetaxel) in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. taxotere (docetaxel) in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. taxotere(docetaxel) monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent. taxotere (docetaxel) in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress her2 and who previously have not received chemotherapy for metastatic disease. taxotere (docetaxel) in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy.
taxotere
sanofi - aventis israel ltd - docetaxel as trihydrate 20 mg / 1 ml - concentrate for solution for infusion - docetaxel - breast cancer: taxotere (docetaxel) in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. taxotere (docetaxel) in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. taxotere(docetaxel) monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent. taxotere (docetaxel) in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress her2 and who previously have not received chemotherapy for metastatic disease. taxotere (docetaxel) in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy.